Bioventus Stock (NASDAQ:BVS)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$11.59

52W Range

$3.67 - $14.38

50D Avg

$11.98

200D Avg

$7.58

Market Cap

$745.85M

Avg Vol (3M)

$525.39K

Beta

0.88

Div Yield

-

BVS Company Profile


Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

1,030

IPO Date

Feb 11, 2021

Website

BVS Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 21
Surgical Solutions$87.72M
Pain Treatments$221.61M
Restorative Therapies$121.57M

Fiscal year ends in Dec 23 | Currency in USD

BVS Financial Summary


Dec 23Dec 22Dec 21
Revenue$512.35M$512.12M$430.90M
Operating Income$16.01M$-35.68M$17.72M
Net Income$-156.23M$-213.39M$9.59M
EBITDA$73.38M$31.13M$52.60M
Basic EPS$-2.49$-3.48$0.16
Diluted EPS$-2.49$-3.48$0.16

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 05, 24 | 12:26 PM
Q2 24Aug 11, 24 | 1:45 PM
Q1 24May 07, 24 | 12:00 AM

Peer Comparison


TickerCompany
RPIDRapid Micro Biosystems, Inc.
TIVCTivic Health Systems, Inc.
NUWENuwellis, Inc.
BBLGBone Biologics Corporation
BJDXBluejay Diagnostics, Inc.
HSCSHeart Test Laboratories, Inc.
NAOVNanoVibronix, Inc.
VVOSVivos Therapeutics, Inc.